3bym
From Proteopedia
Line 1: | Line 1: | ||
{{Seed}} | {{Seed}} | ||
- | [[Image:3bym. | + | [[Image:3bym.png|left|200px]] |
<!-- | <!-- | ||
Line 12: | Line 12: | ||
===X-ray co-crystal structure aminobenzimidazole triazine 1 bound to Lck=== | ===X-ray co-crystal structure aminobenzimidazole triazine 1 bound to Lck=== | ||
+ | |||
+ | <!-- | ||
+ | The line below this paragraph, {{ABSTRACT_PUBMED_18278858}}, adds the Publication Abstract to the page | ||
+ | (as it appears on PubMed at http://www.pubmed.gov), where 18278858 is the PubMed ID number. | ||
+ | --> | ||
+ | {{ABSTRACT_PUBMED_18278858}} | ||
==Disease== | ==Disease== | ||
Line 17: | Line 23: | ||
==About this Structure== | ==About this Structure== | ||
- | 3BYM is a | + | 3BYM is a 1 chain structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3BYM OCA]. |
+ | |||
+ | ==Reference== | ||
+ | Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity., Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG, J Med Chem. 2008 Mar 27;51(6):1637-48. Epub 2008 Feb 16. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/18278858 18278858] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Non-specific protein-tyrosine kinase]] | [[Category: Non-specific protein-tyrosine kinase]] | ||
- | [[Category: Single protein]] | ||
[[Category: Huang, X.]] | [[Category: Huang, X.]] | ||
[[Category: Alternative splicing]] | [[Category: Alternative splicing]] | ||
Line 42: | Line 50: | ||
[[Category: Tyrosine-protein kinase]] | [[Category: Tyrosine-protein kinase]] | ||
- | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Dec 31 09:02:33 2008'' |
Revision as of 07:02, 31 December 2008
Contents |
X-ray co-crystal structure aminobenzimidazole triazine 1 bound to Lck
Template:ABSTRACT PUBMED 18278858
Disease
Known disease associated with this structure: SCID due to LCK deficiency OMIM:[153390]
About this Structure
3BYM is a 1 chain structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity., Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG, J Med Chem. 2008 Mar 27;51(6):1637-48. Epub 2008 Feb 16. PMID:18278858
Page seeded by OCA on Wed Dec 31 09:02:33 2008
Categories: Homo sapiens | Non-specific protein-tyrosine kinase | Huang, X. | Alternative splicing | Atp-binding | Chromosomal rearrangement | Cytoplasm | Disease mutation | Host-virus interaction | Kinase domain | Lck | Lipoprotein | Membrane | Myristate | Nucleotide-binding | Palmitate | Phosphoprotein | Proto-oncogene | Sh2 domain | Sh3 domain | Transferase | Tyrosine-protein kinase